Drugs / Methocarbamol
Methocarbamol
also known as
Robaxin · Delaxin · Forbaxin · Methocarbamol component of robaxisal · Metocarbamol · Miolaxin · Neuraxin · NSC-170960 · +1 more
Small molecule targets CA1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ROBAXIN-750 | — | 1957-07-16 | fda.gov ↗ |
Trials 5
19561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 33 trials | ||||||
| Phase 3 | NCT02642874 | Apr 2017 → Dec 2020 | cirrhosis of liver | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT02831569 | Jul → Oct 2016 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01979510 | Nov 2013 → May 2014 | — | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05388929 | Jun 2022 → Jun 2027 expected | abdominal wall malformation | Prisma Health-Upstate | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05076110 | Apr 2022 → Oct 2025 | — | Mayo Clinic | Completed | No outcome recorded |
| Comparator or background therapy10 trials | ||||||
| Phase 3 | NCT07296770 Background | Oct 2026 → Dec 2028 expected | chronic pain syndrome | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06561035 Background | Sep 2024 → Dec 2027 expected | — | Campbell Clinic | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT05603832 Background | Nov 2022 → Nov 2023 | — | Arthritis Innovation Corporation | Completed | No outcome recorded |
| Phase 4 | NCT07866638 Background | Nov 2026 → Sep 2028 expected | — | University of Alabama at Birmingham | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05144828 Background | Feb 2022 → Oct 2024 | lung disorder, neuropathy, painful | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 4 | NCT04990804 Background | Aug 2021 → Feb 2022 | spinal cord disorder, substance-related disorder | Vanderbilt University Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT02665286 Comparator | Mar 2016 → Apr 2017 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02432456 Background | Sep 2015 → Aug 2018 | — | Medical College of Wisconsin | Completed | Missed primary |
| — | NCT05100017 Comparator | Sep 2021 → Jun 2025 overdue | nephrolithiasis, ureterolithiasis | Northwestern University | Active not recruiting | No outcome recorded |
| — | NCT06583551 Comparator | Jan → Mar 2021 | bruxism | University of Health Sciences | Completed | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Methocarbamol | “Pharmacological treatment was administered by prescribing Miyorel, a combination of methocarbamol (380 mg) and paracetamol (300 mg).” NCT06583551 ↗13“5. Methocarbamol (Robaxin) 750mg twice per day from postoperative day 1 to postoperative day 14.” NCT06561035 ↗ “a muscle relaxer (Methocarbamol 750mg BID or Flexeril 5-10 mg TID)” NCT04990804 ↗ “DOLOCAM PLUS® (meloxicam 7.5mg/methocarbamol 215mg)” NCT01979510 ↗ “methocarbamol 750mg three times daily” NCT07866638 ↗ “Methocarbamol” NCT07296770 ↗ |
| Known as | Delaxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201117 ↗ |
| Known as | Forbaxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201117 ↗ |
| Known as | Methocarbamol component of robaxisal | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201117 ↗ |
| Known as | Metocarbamol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201117 ↗ |
| Known as | Miolaxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201117 ↗ |
| Known as | Neuraxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201117 ↗ |
| Known as | NSC-170960 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201117 ↗ |
| Known as | Robaxin | “5. Methocarbamol (Robaxin) 750mg twice per day from postoperative day 1 to postoperative day 14.” NCT06561035 ↗2“This includes tylenol 650 mg oral, robaxin 500 mg oral, and tramadol 25-50 mg oral.” NCT05144828 ↗ “Robaxin” NCT02432456 ↗ |
| Known as | Robaxin-750 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201117 ↗ |
| Action | Inhibit | “Carbonic anhydrase I inhibitor” CHEMBL1201117 ↗ |
| Modality | Small molecule | — CHEMBL1201117 ↗ |
| Route | Oral | “500 mg orally every 6 hours” NCT02432456 ↗ |
| Target | CA1 | “Carbonic anhydrase I inhibitor” CHEMBL1201117 ↗ |